Andrew J. Schwab Net Worth

The estimated Net Worth of Andrew J. Schwab is at least $2.95 million dollars as of 26 May 2020. Andrew Schwab owns over 578,034 units of scPharmaceuticals Inc stock worth over $2,953,754 and over the last 11 years Andrew sold SCPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Schwab SCPH stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the scPharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Andrew bought 578,034 units of SCPH stock worth $4,999,994 on 26 May 2020.

The largest trade Andrew's ever made was buying 578,034 units of scPharmaceuticals Inc stock on 26 May 2020 worth over $4,999,994. On average, Andrew trades about 192,678 units every 0 days since 2014. As of 26 May 2020 Andrew still owns at least 578,034 units of scPharmaceuticals Inc stock.

You can see the complete history of Andrew Schwab stock trades at the bottom of the page.

What's Andrew Schwab's mailing address?

Andrew's mailing address filed with the SEC is 501 2ND STREET, SUITE 350, , SAN FRANCISCO, CA, 94107.

Insiders trading at scPharmaceuticals Inc

Over the last 7 years, insiders at scPharmaceuticals Inc have traded over $5,999,254 worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth $61,370,807 . The most active insiders traders include Capital Management, L.P.Ra ..., Jonathan Silverstein et Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of $1,808,281. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth $29,275.

What does scPharmaceuticals Inc do?

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.

Complete history of Andrew Schwab stock trades at Flexion Therapeutics Inc et scPharmaceuticals Inc

scPharmaceuticals Inc executives and stock owners

scPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Tucker,
  President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director
• John H. Tucker,
  Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director
• Rachael Nokes,
  Senior Vice President - Finance, Principal Accounting Officer
• Rachael Nokes,
  Sr. VP of Fin. & Principal Accounting Officer
• Jack Khattar,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• Mette Agger,
  Independent Director
• Klaus Veitinger,
  Independent Director
• Minnie Baylor-Henry,
  Independent Director
• Leonard Schaeffer,
  Independent Director
• Mason Freeman,
  Independent Director
• Katherine Taudvin,
  Director, Corporate Development, Investor Relations
• Sara Bonstein,
  Independent Director
• Michael D. Hassman,
  Sr. VP of Technical Operations
• Dr. John Mohr Pharm.D.,
  Sr. VP of Clinical Devel. & Medical Affairs
• Capital Management, Llcra C...,
  
• Invest A/S Lundbeckfond,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Dorothy Coleman,
  Director
• Jonathan Silverstein,
  Director
• Pharmaceutical Industries L...,
  
• Troy A. Ignelzi,
  Chief Financial Officer
• Abraham Ceesay,
  Chief Operating Officer
• Kush Parmar,
  Director
• Andrew J. Schwab,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Partners Iv, Llc5 Am Co Inv...,
  
• William Tober Abraham,